Evidence map›Paper›PMID 41293618›Full record

ReviewFrontiers in cardiovascular medicine2025

Cardiovascular manifestations in mast cell activation disease: key insights for cardiologists and angiologists.

Wolfgang Taumann, Gerhard J Molderings

Abstract readReview
In one paragraph

Review in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Wolfgang TaumannMast Cell Sciences Ltd., Meckenheim, Germany.
Gerhard J MolderingsInstitute of Human Genetics, University Hospital of Bonn, Bonn, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mast cell activation disease is a genetic disease entity characterized by a very pronounced clinical symptomatology with potential manifestations in virtually every organ and tissue. These arise from the inappropriate release of mast cell mediators and the accumulation of both morphologically normal and mutated mast cells. Owing to the high prevalence of the disease-estimated to be up to 17%-cardiologists and angiologists are frequently confronted with mast cell activation disease in their daily clinical practice, often without recognizing it. Therefore, every cardiologist and angiologist should possess basic knowledge about this disease and be aware of its cardiovascular challenges. This review summarizes the current state of knowledge on this highly complex disease, with a particular focus on the cardiovascular aspects.

Indexed as

cardiovascular symptomsmast cell activation diseasemast cell activation syndromemast cell mediator release syndromemast cell mediatorssystemic mastocytosis

Identifiers

PMID41293618
PMCPMC12641438

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.